{"text_format":"3","workbook":"xls","n_sheets":3,"sheets":["Sheet1","Sheet2","Sheet3"],"not_rendered":{"external_links":1,"defined_names":1},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Sheet1","index":0,"n_rows":79,"n_cols":4,"rows_kept":79,"merged":[[46,0,47,0],[46,3,47,3],[59,0,60,0],[59,3,60,3],[72,0,73,0]],"flags":["formulas_cached_only"]}
["Table 1 Patient characteristics"]
[null,"enrolled (n=73)","excluded (n=295)","P value"]
["Age at diagnosis, years",null,null,0.9486]
["  ≤40",16,56]
["  41-45",25,103]
["  46-50",24,100]
[" ≥51",8,36]
["Tumor stage",null,null,0.5808]
["  T1",29,95]
["  T2",30,147]
["  T3",8,30]
["  Tx",6,23]
["Positive LN",null,null,0.6185]
[0,40,166]
["  1-3",17,72]
["  4-9",9,41]
["  ≥10",7,16]
["Receptor status",null,null,0.0052]
["  ER+,PR+",43,102]
["  ER+,PR-",8,53]
["  ER-,PR+",9,67]
["  ER-,PR-",10,56]
["  Unknown",3,17]
["Her-2/neu",null,null,"<0.0001"]
["  Positive",25,66]
["  Negative",40,103]
["  Unknown",8,126]
["Chemotherapy regimen",null,null,0.9299]
["  TEC",3,15]
["  FEC",20,79]
["  FEC-T",19,82]
["  TC",17,77]
["  TCH",3,10]
["  TE",11,32]
["Radiation therapy",null,null,0.0529]
["  Yes ",36,109]
["  No ",37,186]
["Tamoxifen ",null,null,0.064]
["  Yes ",64,230]
["  No ",9,65]
["Trastuzumab",null,null,0.8172]
["  Yes ",7,31]
["  No",66,264]
["ER, estrogen receptor; PR, progesterone receptor; TEC, docetaxel, epirubicin, cyclophosphamide; FEC, 5-fluorouracil, epirubicin, cyclophosphamide; FEC-T, FEC, docetaxel; TC, docetaxel, cyclophosphamide; TCH, docetaxel, carboplatin, trastuzumab; TE, docetaxel, epirubicin."]
[]
["Table 2 Univariate analysis of CIA"]
[null,"Amenorrhea","No amenorrhea","P value"]
[null,"(n=61)","(n=12)"]
["Age at diagnosis >40 y, n (%)","54 (88.5)","3 (25.0)","<0.0001*"]
["Chemotherapy regimens, n (%)",null,null,"0.3333*"]
["  Anthracycline-based regimen(FEC)","16 (26.2)","4 (33.3)"]
["Taxane-based regimen(TC, TCH)","19 (31.1)","1 (8.3)"]
["  Anthracycline- and taxane- based regimen(TEC,FEC-T,TE)","26 (42.6)","7 (58.3)"]
["Tamoxifen, n (%)","55 (90.2)","9 (75.0)","0.1608*"]
["Radiation therapy, n (%)","30 (49.2)","6 (50.0)",0.9586]
["Trastuzumab, n (%)","7 (11.5)","0 (0)","0.5911*"]
["* Fisher's exact tests; # As there was only 12 patients without amenorrhea, these analysis is limited."]
[]
["Table 3 Univariate analysis of menopause"]
[null,"menopause","No menopause","P value"]
[null,"(n=22)","(n=51)"]
["Age at diagnosis >45 y, n (%)","19 (86.4)","13 (25.5)","<0.0001"]
["Chemotherapy regimens, n (%)",null,null,0.9996]
["  Anthracycline-based regimen(FEC)","6 (27.3)","14 (27.5)"]
["Taxane-based regimen(TC, TCH)","6 (27.3)","14 (27.5)"]
["  Anthracycline- and taxane- based regimen(TEC,FEC-T,TE)","10 (45.4)","23 (45.0)"]
["Tamoxifen, n (%)","22 (100.0)","42 (82.4)","0.0313*"]
["Radiation therapy, n (%)","11 (50.0)","25 (49.0)",0.9287]
["Trastuzumab, n (%)","2 (9.0)","5(9.8)","1.0000*"]
["* Fisher's exact tests"]
[]
["Table 4 Age group and menstrual status"]
[null,"≤40 years","41-45 years","46-50 years"]
[null,"(n=16)","(n=25)","(n=24)"]
["CIA, n (%)","7 (43.8)","22 (88.0)","24 (100.0)"]
["Final menstrual status, n (%)"]
["Regained menses","7 (43.8)","15 (60.0)","5 (20.8)"]
["Amenorrhea with postmenopausal hormone levels (menopause)",0,"3 (12.0)","14 (58.3)"]
["Amenorrhea with premenopausal hormone levels",0,"4 (16.0)","5 (20.8)"]

{"sheet":"Sheet2","index":1,"n_rows":0,"n_cols":0,"rows_kept":0,"flags":["formulas_cached_only"]}

{"sheet":"Sheet3","index":2,"n_rows":0,"n_cols":0,"rows_kept":0,"flags":["formulas_cached_only"]}